Escape from the Heat

In 2006, Thai authorities set a precedent by forcibly licensing Merck’s Efavirenz for HIV therapy, thus enabling the legal production of its generics. A year later, the same thing was done in Brazil. Does it mean that the situation with HIV and other socially significant diseases (SSD) in those countries had reached a critical level and the local authorities had to take such drastic measures at the risk of spoiling relations with the world’s largest pharmaceutical companies? How acute is the problem today, 10 years later?

The actions of the authorities in Thailand and Brazil were absolutely a necessity at that time. Both countries have a very serious problem with HIV infections. People had to be treated, but they could not afford to pay for the medicine at the price requested by the originator. Negotiations with the companies to reduce the price brought no results. Accordingly, in the end, they adopted a scheme of compulsory licensing, produced the drugs, and people received treatment.

At the same time, it’s worth mentioning that although there really were concerns that such actions could complicate relations with the developers of the original medicines, that they could even leave those countries under the pretext that they had been robbed and their innovations taken away from them, nothing of the sort happened. Moreover, the manufacturers of the original drugs became more disciplined. Which is why, in Brazil, such stories no longer occur. If the government goes out and says, “Guys, you have to reduce the prices,” the pharmaceutical companies clamor to oblige. When something is truly needed, when it comes to human lives, then you have to be a little more socially responsible.

Talking about the situation with HIV and other SSDs in developing countries in general and in the BRICS countries in particular, the problem, unfortunately, still remains very acute. The only salvation would be the availability of drugs. If people get the necessary medicines, then at least they will not infect others. It has been shown that if people are undergoing treatment, they are not dangerous to their partner.

Over the past eight to 10 years, all the BRICS countries, without exception, have taken serious measures and implemented real programs to combat HIV. Among other things, they involve providing infection carriers with the necessary free medications. But, I repeat, the problem is still acute everywhere.

Are the BRICS countries capable of independently developing and manufacturing such medications? Is there a necessary production and scientific capacity for this?

Each of these countries is self-sufficient in the development of key drugs. Each of them has enough intellectual property. For instance, let’s look at us, Russia and Pharmasyntez. We now have around 300 candidate molecules in development that could potentially become drugs against HIV. We will have to see which of them will be successful, which of these molecules will actually reach the clinical studies and show antiretroviral effectiveness. The problem is different: There are no powerful pharmaceutical companies that could invest enough money into development in any of these countries. This is a big drag on progress toward innovation in pharmaceuticals, although there is enough brainpower, especially in Russia. There are scientists here who can really develop drugs and do a lot in this area.

Do you work with them?

We cooperate with leading institutes and universities in the country, particularly in Irkutsk, Novosibirsk, St. Petersburg, and Moscow. I will tell you a terrible secret: More than 90 percent of such developments are being designed by universities and scientific institutions rather than pharmaceutical companies who like to talk about themselves as innovators and developers. They are being, to put it mildly, less than truthful about this. Therefore, we support those institutions; we work with them every day. And, of course, we wish to cooperate with colleagues from BRICS, both in the area of development and in the area of introducing new drugs. We always welcome all developers of innovative drugs from the BRICS nations as well as other countries. We are prepared to launch, register, and provide so-called ‘market access’ for these drugs.

Newton’s apple

Could the solution be a decision to unite the efforts of the BRICS countries in the development of innovative drugs?

The combining of efforts makes sense when bringing ready-made products to the market. For example, if there were a joint center for innovative drugs, one could register and license finished medicines for all the BRICS countries. Then, we would immediately get a large market and a rapid dissemination of modern drugs in all these countries.

As for joint development itself, from my real-life experience, I do not see any objective possibility for such cooperation.

Why?

I will mention only one, but very important, reason: intellectual property. It cannot be public. It is the property of a specific developer. An idea may be public – which medicine to produce, for example – but the development itself cannot be done by a huge number of people. Only a small group of scientists, or even one particular scientist, develops something. And after that, this design cannot be the property of the entire BRICS group.

Intellectual property is always the fruit of someone’s individual labor. For example, the law of universal gravitation was formulated by a specific scientist, Isaac Newton, rather than the country of Great Britain.

But it is impossible to create a modern compound by yourself, sitting under an apple tree in your own garden. Even if you have a brilliant idea, you need scientific infrastructure and funding to bring it to fruition.

That is the nature of an idea – it can come to a person in the garden or in the bathroom. It is an indispensable thing. Projects are born based on ideas, and not vice versa. Just because you plunk yourself down in some high-tech building full of equipment behind a glass wall – are you telling me that you will make a new drug? No way.

I repeat: The overwhelming majority of new medicines are created all over the world in universities and other such institutions. Only a very small minority are actually developed by the pharmaceutical companies that pretend they are such great innovators. So, all these universities and institutions already exist in all the BRICS countries – no new infrastructure needs to be built. Moreover, in my opinion, they are the only ones able to really carry out this work. If you stick them in a heap under some beautiful roof and give them an assignment, “Guys, make us a new cure for the HIVs,” they won’t be able to.

We have already seen such examples. In 2012, seven world pharmaceutical companies – Abbott, AstraZeneca, Bayer, Eli Lilly, GlaxoSmithKline, Merck, and Sanofi – entered into a partnership agreement that was to accelerate the creation of innovative medicines for the treatment of tuberculosis. They planned to develop three drugs, the use of which would have cured tuberculosis in one month. They allocated a lot of money for this. So, where are these drugs?

It is difficult to expect that the pharmacological companies will destroy a huge market with their own hands by creating a drug that would cure everybody once and for all. It’s like expecting bees to destroy honey.

This is a well-known stereotype that has nothing to do with reality. For example, a recently-developed drug against hepatitis cures this disease in 98 percent of cases. If everybody is treated correctly, then soon the problem of hepatitis will be solved all over the world.

What will the pharmaceutical companies do after this?

They will find something else. There will be new diseases. They, too, will have to be treated. There is no mafia that prevents new drugs from entering the market. This is nonsense. There is nothing like this in the world. I can responsibly talk about this as a pharmacist who understands this from within.
Therefore, coming back to your first question, the governments of each of these countries should take measures to support these universities and specific scientists, not create any artificial organizations. For example, tell me, to date, what is the result of Rosnano or Skolkovo?

Not enough time has passed to evaluate their work. Investments in venture capital are always long-term.

Well, Godspeed to them. Let’s hope that in about 10 or 15 years we will get some super-helicopter or super-technology. But I personally won’t hold my breath. I believe that it is necessary to directly support those in the universities who spend their entire life working on one problem or another. For example, there is an institute of virology, where people work 50 to 60 years, and they know everything about viruses. So they are able to develop something. Otherwise, it does not matter what kind of super-duper piano they give you or how much money you get paid, if you can not play piano, you will not be able to perform Rachmaninov.

Okay. Suppose there was a man somewhere who came up with the idea of how to make a pill that cures HIV or hepatitis. It is a long way from the idea to the manufacturing of the pill. How do you go about it?

This is a very important issue. I believe that out of all BRICS countries, Russia suffers the most due to the fact that products do not reach the market. Although, recently, the situation has become a little better. Why? Because Russia is really the most innovative of these five, first of all, thanks to its Soviet legacy.
This problem will be possible to solve when Russia has at least five to seven large pharmaceutical companies with a turnover of at least a billion dollars a year. This will give them sufficient resources to fully fund innovation. It is possible – I’m not fantasizing or exaggerating.

It was probably fate

And yet, it sounds like fiction.

Everything is real. For example, 20 years ago, I started my business from scratch – at the time, I was a student at Irkutsk State Medical University (ISMU). There was nothing. We started with one plant in Irkutsk, which produced one anti-tuberculosis drug. Now, we make about 150 compounds; we now manufacture virtually all forms of drugs that exist in pharmaceutical production. We are the leader in Russia when it comes to anti-tuberculosis and antiretroviral drugs. Pharmasyntez now has five manufacturing facilities all over the country, from St. Petersburg to Vladivostok, one-and-a-half-thousand employees, more than $200 million in turnover, and our capitalization is about $1 billion. We are growing at a rate of 50 to100 percent per year. I do not know where we will be in 2020, but we will try very hard to be on the list of manufacturers with revenues of over $1 billion. So, as you can see, no fiction there.

How did you manage to build such a business? How on Earth did a person from India get the idea to go to Russia to manufacture medicines here?

To make a long story short, first of all, I had a huge passion, which, moreover, was supported by real ideas. The second reason is confidence in one’s actions. If you think that you are right, you must be strong enough not to be afraid to make decisions. Those decisions eventually helped me build a company from scratch.

What do you mean?

I was not afraid to make bold decisions. For example, the decision to open the first manufacturing facility in Irkutsk in the very beginning of the 1990s, immediately after the collapse of the USSR, or to invest in business in 1998 against the backdrop of a collapse of the ruble and complete economic collapse. You would think, how can you invest in such a country? But I was convinced that medicines in Russia were needed – medicines that we ourselves produce – that there were not enough of them, and that they would always be needed. At that time of crisis, I took all my money – before that, I earned a little through small trade – and invested in business. I took out loans and invested. I was not afraid to make such a decision. Obviously, if I did not succeed, then the banks and the lenders would take my last shirt. But I was not afraid. I understood that everything I did was right. I made the right decisions. That is, I had the courage and the confidence to do what I thought was right.

You started with several Russian partners.

Yes, and that turned out to be a problem. They hampered the development of the business. They lacked elementary charisma, confidence, and courage in decision-making. And thank God they did. In 2009, I bought out all of Pharmasyntez’s shareholders. After that, in six years, our revenue has grown more than 10 times.

Has your Indian heritage affected your life and your business in Russia somehow?

I do not want to toot my own horn, but I think that if I lived in Japan or in America, I would most likely do the same thing, in any country. You are a human being. If you have a head on your shoulders, then do something, work at it. On the other hand, luck is also a very important factor.

Of course, you can have good ideas, but passion, courage, and luck play a very important role in business. These are the main factors. As for communication, throughout all this time, I honestly did not experience any problems – not with people, nor with officials, nor with business partners. I think I completely integrated into Russian society and life in Russia, maybe because my mentality has changed very quickly. I think that this is in large part due to the fact that in India I studied in a first-class school, which, among other things, taught me to communicate with people.

What was so special about your school?

It was Birla Higher Secondary School, the best in Pilani. There, I also got lucky. My father paid a lot of money – he is a fairly wealthy person – for me to study at that school. For this, I am very thankful to him. It gave me a lot. The education followed the British system. All studies were in English. We had our own campus, where we lived all the time. It was simple: We had to get up at five in the morning. There were exercises, discipline, and order in everything. We received good instruction, we had good teachers, and it really was an excellent education.

Education or upbringing?

Both education and upbringing. In addition to studying, almost all of us knew how to ride a horse, how to swim, and how to perform on stage. Each student was required to choose the kind of sport he or she would be engaged in, taking into account everyone’s ability, of course. But in any case, we were engaged in something from five in the morning to 10 in the evening. We were really brought up right. And I know that most of those who studied there are successful people today. They live in different countries, although, naturally, most of them live in India.

In general, I believe that school education is the most important thing in the life of any person. Not college. Nobody else can ever give you what your school gives you.

After the elite Indian school, you immediately ended up in a provincial Russian university – the Irkutsk State Medical Institute. How did it happen? Why Russia? Why Irkutsk?

It was probably fate. I see no other way to explain it. But the real reason is that I really do not like and do not tolerate heat. When it’s 40°C in the street, I get a fever. So, I often got sick in my childhood. After graduation I entered a very good medical university in India, but I had thoughts of going to some cold country, just so that there wouldn’t be all that heat.

In other words, you poked an ice cap on a map and ended up in Irkutsk?

No, not exactly. I saw an announcement at my university about recruiting students for an exchange program. There were different countries to choose from, including Russia. It was a government program financed by the government of India. For some reason, I chose Russia, although I also considered Europe and Australia. I passed the exams, got very good grades; I was always good at studying, I had never had any problems with my studies. And there again, fate intervened.

It was 1991, the collapse of the USSR. At first, they wanted to send me to Uzbekistan, to Tashkent. Then I said that although I had never been to either Russia or Uzbekistan, I still understood basic things. In fact, I gave them an ultimatum: Either our arrangements were canceled and I could continue my studies in India, or I would be sent to Russia. I wanted to go to Moscow. It so happened that I was offered Irkutsk.

And you agreed?

Unfortunately, at the time, there was no Google, so I could not immediately see what kind of city and region it was. But, somehow, intuitively, I thought that maybe everything would be fine. I asked around. First of all, they confirmed to me that it was really much colder there than in India. And then they said that there was a very good university there, IGMU, where I eventually transferred.

That’s when I discovered the situation. I did not know the language – not a word in Russian. Conditions were very harsh. It was very, very cold. There were a couple of dozen foreign students. Almost everyone returned back home. But I had confidence in myself: I had to learn without paying attention to anything else. I just had to wear warmer clothes. As a result, only two people remained in the program. One of those two was me.

I had no plans to stay in Russia after my studies or do some kind of business. But it seemed to happen by itself.

How so?

You know, our life consists of little things. In general, everything happened by itself somehow. And I do not regret it. Although, recently, I thought to myself, I could have become an actor.

But it seems that all Indians are actors anyway?

Not all. And, nevertheless, I believe that everything I do, I do well and I do it correctly. Then, I already told you: Today, 20 years later, we are the most dynamically growing Russian pharmaceutical company in the county, worth a billion dollars, and, I hope, with a billion turnover within three years.

Through our efforts, I think, we have made Russia self-sufficient in the area of anti-tuberculosis drug manufacturing and soon, I hope, we will do the same in the area of drugs for HIV treatment. Partially through our efforts, Russia has become an exporting country of these medicines. Earlier – about 15 years ago – it imported almost 100 percent of them. Everything came from abroad. Not only have we changed all that, we are already exporting them to seven or eight countries.

For export

Which countries?

Basically, all of them are CIS countries.

What about beyond the former USSR?

We are in the process of registration and negotiations. I think that if everything goes well, then we will have been in at least 50 countries by the year 2020.

What kind of medicines are we talking about?

Of course, we are also interested in exporting our innovative medicines for the treatment of tuberculosis. Let me remind you that in Russia, Pharmasyntez is the only company that has produced an original drug for the treatment of this disease – Perchlozon. It was developed and put into medical practice in 2012, and it has been patented in more than 100 countries around the world. The fourth phase of clinical trials is currently underway. I am sure that at least this drug will be sold in more than 50 countries globally by 2020.

We have also developed a drug to prevent postoperative adhesions – Seroguard. Such adhesions are a big headache for surgeons. Today, the world does not have such a drug that really works. We were the first to develop it. We successfully conducted preclinical and first-phase clinical trials, and we are now in the second phase of clinical trials. If everything goes well, we will bring it to market in 2019. In parallel, we began to register this drug in the US, where we are going to start deliveries before 2020. If we are lucky and the drug is successful, then I am sure that it will be a revolution in the field of surgery.

And of course, as I have already mentioned, we have developed about 300 candidate molecules for the treatment of HIV.

Our next big task will be cancer drugs. We have recently opened a state-of-the-art facility in St. Petersburg for the manufacture of cancer drugs, investing about 2.5 billion rubles ($45 million). Our goal is, first and foremost, to make sure that virtually all existing innovative drugs for the treatment of cancer are manufactured in Russia. Then, we will start exporting these medicines. I would even say that we are most interested in cancer treatments when it comes to exporting pharmaceuticals.

Of course, other areas are also interesting, but it is too early to talk about them. I hope that in 2020 we will meet again and discuss how far we have come. You know, journalists came to talk to me in 2011. I think, at the time, we had about $40 million to$50 million in turnover. And I told them, “Guys, in five years, we will have a quarter of a billion.” That was my forecast then. We almost managed to do it, too. If the devaluation had not happened in 2014-2015, we would have achieved this goal. Our revenue exceeded 12 billion rubles ($215 million); using the old exchange rate, it would have been about $400 million. So, we more or less manage to do whatever we set out to do.

The government and us

Is Pharmasyntez mentioned as part of the government strategy of pharmaceutical industry development in Russia?

Yes, we are on different lists.

Does the government help you at all?

It does help, and that helps. It helps so much that sometimes, I think that without this help, it would be impossible to develop so quickly now. First of all, the Ministry of Industry and Trade and the Pharma-2020 strategy help. If not for this ministry, the Russian pharmaceutical business would have had a difficult time. I believe that they are implementing the task set by the Russian government extremely well. We recently had an exhibition where we announced assistance we had received from the government worth about 300 million rubles ($5.4 million) in the form of subsidies, trade preferences, and benefits.

The second theme is the Industrial Development Fund. We are the first Russian pharmaceutical company that received a preferential loan for 300 million rubles. This is a relatively small amount, but the very fact that the government supports us is important.

Further, we receive subsidies for clinical studies that we carry out. We also receive subsidies for the money that we invest in pharmaceutical production. I need to mention that today, Pharmasyntez is one of the leading investors in Russian pharmaceutical production. For the last 2.5 years, we have invested almost 10 billion rubles. In Russia, I do not know any other such company.

We also receive subsidies on loans. Almost 70 percent of the rate on our loans is repaid by the Ministry of Industry and Trade.

When I started doing business, I did not even think it was possible. This has been happening in the last five to seven years. Before that, nothing like this ever happened. Even in 2008, it was difficult to imagine that something like this would happen.

Are you only supported on the federal level?

Not only. There are some regions, too, although, not so many of them support us very effectively. I would single out the Tyumen region and its governor, Vladimir Yakushev. They have very advanced leadership over there, and they are interested in business development. I have never seen anything like this anywhere else in Russia.

Actually, thanks to this positive attitude on the part of the governor, in 2015, we went there, invested a huge amount of money in a bankrupt enterprise, it was eventually launched, and now, it works in 24/7 mode, without breaks, holidays, or weekends.

What facility is this?

It was an enterprise owned by Yugra-Farm. At one time, it was built using public money, and then given to the pension fund – it’s a long story. They could not manage their business, and the company went bankrupt, the employees ended up on the street, and everyone was in debt. Once we met with Vladimir Yakushev at the St. Petersburg International Economic Forum, we started talking. He asked what I needed, what support and help was needed to revive the plant. Only one thing was needed from me: to make everything work again, to benefit both people and the country. I gave my terms, and without any bureaucracy, he gave his team a week to work it out.

They did it. We came to an agreement; we made the necessary decisions; we invested. We bought both the company and the equipment. We got support and we are still getting it. So, today, we are planning to direct a lot of investment to the Tyumen region.

For my part, I would like to give one message to the BRICS businessmen who want to invest in Russia: Look at the Tyumen region. If you have ideas, if you want to invest money, this is one of those places where you will be supported, where there really is every opportunity for investment.

All in all, the role of the government is very important, and we do feel this support and assistance.

Big pharma, Korea style

If you were an official, what would you do for the development of the Russian pharmaceutical industry? Where do you see it in five to 10 years?

This is a risky premise; some officials might think that I am after their jobs. Let me reassure them – no, not at all. Nevertheless, my vision is as follows: The government should choose five to seven of the most advanced, large, fast-growing pharmaceutical companies in the country and create a separate development program with them. Give them a direction, and support them in all respects – financially as well as through regulations and administratively. Support for export is needed, as well as government guarantees and compensation of interest rates on loans. That is, it is necessary to render assistance to these companies in all aspects of their development.

Only them?

Of course, this does not mean that there is no need to support others. Other companies should also be given opportunities, but it is necessary to create the most favorable conditions for five to seven companies that can really become Big Pharma in Russia. As Russian Prime Minister Dmitry Medvedev recently said, by 2035, at least five global Big Pharma companies should be of Russian origin, or simply put, Russian.

In other words, you are calling for the cultivation of champions using, let’s put it this way, the Chinese or South Korean model?

Exactly. People laughed when Samsung was bought in the 1980s. And now, no one can compete with that company – not Sony, nor Panasonic, nor Philips. Today, there is a world leader in electronics: Samsung. Even with all the scandalous stories that we have heard recently in connection with this company, it does not matter.

Therefore, we must grow them. Support them. Make a program with them. If we start this work today, by 2035 – even sooner, in fact – there will be pharmaceutical companies that will represent Russia on the world stage. It’s possible.

What plans does Pharmasyntez have?

As for us, we are planning further expansion no matter what. If we get support, we will develop faster; if we don’t, it will take longer, but we will anyway, because there are companies that, despite everything, will push forward whether they get support or not. Believe me, Russia already has five to seven such companies today. That’s first.

Secondly, it is necessary to improve the regulatory regime. For example, now, we are discussing one very important law on the three-tier system of admission of pharmaceutical companies to public procurement auctions. In my opinion, it is necessary to introduce this scheme. It prescribes that companies manufacturing substances in Russia – that is, raw materials for pharmaceutical production – will get priority in getting government contracts.

We talked about pharmaceutical products not reaching the market in Russia. But how will they reach the market if we do not have a culture of manufacturing substances? Suppose a scientist has developed a molecule. There must be at least five to seven platforms where he could turn to produce a pilot batch of these molecules. Right now, we do not have such platforms. They need to be developed. In general, it is necessary to create a culture of pharmaceutical manufacturing. If we want to develop such a culture, then domestic production of substances is necessary. But such production of substances will never happen if the government does not regulate this industry. I’m talking about supporting domestic manufacturers in the form of a three-stage admission system.

The skeptics warn that this will lead to an increase in the cost of domestic drugs and, ultimately, the growth of budget spending on their purchase. What do you say to that?

The country will not lose anything on this score. Some say that the price will be high because there will be a monopoly in the market. Recently, we had a meeting with Deputy Prime Minister Arkady Dvorkovich on this topic. We proposed to establish reference prices and demonstrate that pharmaceutical manufacturers will not sell the medicine above the prices existing on the market today due to the fact that they themselves produce the substance. And that’s it. The country does not lose anything. But there will be a culture of manufacturing substances. This will give an impetus to the development of an entire pharmaceutical culture in Russia, from R&D to the patient.

This, briefly, is what I think the government should do today. I think that by 2025 – which is not so far away – the Russian pharmaceutical market will grow from the current approximately $20 billion to $50 billion. Imagine if domestic companies produced 80 percent of what is consumed domestically. That’s the Korean model. This is how the South Koreans did it.

That is, $40 billion worth of domestic pharmaceutical products. Today, it seems like a fantasy, but if you approach it correctly, there is nothing fantastical about it. In Russia, there will be five companies with a turnover of more than a billion dollars a year. They will be able to claim their rightful place in World Pharma by 2035.

But for this to happen, we need to think about this now. Believe me, when I was at university, when I first started doing business, I could never have imagined that I would target billion-dollar capitalization. But I used my head, I did what was necessary, and I moved forward. So, if we move forward – and not just us, as in Pharmasyntez, but the pharmaceutical industry of our country in general – it is quite possible to achieve this goal.

As for our company, I have already said that we are not going to stop. Whether it will be easy or hard is all the same; we will strive forward. Unlike the way things were before 2009, we now have everything needed – the right people, resources, opportunities, and knowledge. We are tenacious, too. We cannot be stopped, and if the government helps us, then we will do it very quickly.

Something to live for

Don’t take it as a provocation, but at what point could you yourself become an object of acquisition by Big Pharma? As you quite rightly noted, buying smaller players with interesting developments is a natural way of expanding business for the world leaders of the industry. Are you ready to consider such proposals?

I will tell you one story. We recently introduced a drug on which we spent about 50 million rubles. We brought it to market well. And then we were offered 800 million for it. At first, this proposal seemed interesting to me: I wouldn’t be selling the company, after all, only one drug out of a 150. But then I thought for a while and decided not to sell it. It’s trite, but I didn’t do it for economic reasons. We know and understand that the economic potential of this drug is much greater than what we were offered. We also know that you won’t find such a team, such ideas, such energy anywhere else but at Pharmasynthez. We do not need to be bought, because I’m afraid it could all fade away.

So what? You would have money. Lots of it.

Let me tell you something: If I stopped working right now, I would not be able to spend all the money I earned for the rest of my life. I would be able to afford everything I wanted, but I still would not be able to spend it. Then, what is the point? Why should I earn more? Money is not the issue, and it does not buy happiness. It is, of course, a philosophical question: What do you live for? Naturally, there are many objectives in life – to give birth to a son, to build a house, to plant a tree.

You could concentrate on much larger problems. For example, Bill Gates uses his money to help save Africa from the very same HIV virus you fight against.

Well, Godspeed to him. He wants to help humanity, he feels his social responsibility. If he can do something good, then he tries to do it. He does not need any more money for sure.

So could you with a lot of money.

I’m doing it now, although so far, just as much as I can. I believe in what we are doing, and tomorrow we will reach a level when we can also have influence. We could make people healthier, make it so that drugs are more accessible, and do something useful for society. These are not just big words. I’m slowly starting to think in this direction. But, right now, we have a great passion to develop further, a desire to grow, to move forward, and to one day get to a point when you can say, yes, now I can definitely do it, I can do it, and it will help.